CY1115366T1 - Δεικτες ογκου - Google Patents

Δεικτες ογκου

Info

Publication number
CY1115366T1
CY1115366T1 CY20141100182T CY141100182T CY1115366T1 CY 1115366 T1 CY1115366 T1 CY 1115366T1 CY 20141100182 T CY20141100182 T CY 20141100182T CY 141100182 T CY141100182 T CY 141100182T CY 1115366 T1 CY1115366 T1 CY 1115366T1
Authority
CY
Cyprus
Prior art keywords
tumour marker
antigens
sample
immune response
cancer
Prior art date
Application number
CY20141100182T
Other languages
English (en)
Inventor
John Forsyth Russell Robertson
Catherine Rosamund Louise Graves
Michael Rawling Price
Original Assignee
Oncimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10831824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115366(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncimmune Limited filed Critical Oncimmune Limited
Publication of CY1115366T1 publication Critical patent/CY1115366T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Μια μέθοδος προσδιορισμού της ανοσολογικής απόκρισης ενός θηλαστικού σε κυκλοφορούσες πρωτεΐνες δείκτες όγκου περιγράφεται στην οποία ένα δείγμα σωματικού υγρού, για παράδειγμα πλάσμα ή ορός, έρχεται σε επαφή με μια σειρά (panel) δύο ή περισσότερων διακριτών αντιγόνων δεικτών όγκου. Η παρουσία συμπλόκων μεταξύ των αντιγόνων δεικτών όγκων και οποιονδήποτε αυτοαντισωμάτων στα αντιγόνα που υπάρχουν στο δείγμα ανιχνεύεται και παρέχει μια ένδειξη μιας ανοσολογικής απόκρισης σε μια κυκλοφορούσα πρωτεΐνη δείκτη όγκου. Η μέθοδος είναι χρήσιμη για τη διάγνωση του καρκίνου, ιδιαίτερα για την ταυτοποίηση νέου ή υποτροπιάζοντα καρκίνου σε έναν ειδάλλως ασυμπτωματικό ασθενή.
CY20141100182T 1998-05-11 2014-03-07 Δεικτες ογκου CY1115366T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9810040.7A GB9810040D0 (en) 1998-05-11 1998-05-11 Blood borne tumour markers
EP05028132.8A EP1731619B1 (en) 1998-05-11 1999-05-11 Tumour markers

Publications (1)

Publication Number Publication Date
CY1115366T1 true CY1115366T1 (el) 2017-01-04

Family

ID=10831824

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100182T CY1115366T1 (el) 1998-05-11 2014-03-07 Δεικτες ογκου

Country Status (12)

Country Link
US (4) US7402403B1 (el)
EP (3) EP1078264B1 (el)
AT (1) ATE314651T1 (el)
AU (1) AU3838899A (el)
CY (1) CY1115366T1 (el)
DE (1) DE69929185T2 (el)
DK (2) DK1731619T3 (el)
ES (2) ES2443096T3 (el)
GB (1) GB9810040D0 (el)
PT (2) PT1078264E (el)
SI (1) SI1078264T1 (el)
WO (1) WO1999058978A2 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20040072264A1 (en) * 2000-12-22 2004-04-15 Morris David W. Novel compositions and methods for cancer
BR0207290A (pt) * 2001-02-16 2005-06-07 Immunivest Corp Método para analisar um paciente quanto à presença de uma malignidade, célula maligna isolada das células cultivadas, vacina de tumor, molécula associada com diátese de tumor alterada, métodos para determinar alterações em moléculas associadas com diátese de tumor como um meio para predizer a eficácia da terapia, como um meio para analisar dosagem apropriada para terapia, como um meio para monitorar eficácia da terapia, como um meio para analisar progressão de câncer, para realizar uma biópsia de corpo inteiro em um paciente, e para identificar alterações em uma célula de tumor circulante relativamente a células presentes numa massa de tumor in situ, e, kit de teste para analisar uma amostra de paciente quanto à presença de uma célula maligna não-hematopoiética
US7214498B2 (en) 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1451587A4 (en) * 2001-11-09 2006-12-06 Benaroya Res Inst At Virginia ANTIGENTAFELN AND METHOD FOR THEIR USE
SI1529060T1 (sl) * 2002-07-22 2015-01-30 Glycotope Gmbh Postopek za proizvodnjo imunostimulacijskih mucinov (MUCI)
GB2424070B (en) 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
US7838305B2 (en) * 2004-03-08 2010-11-23 The United States Of America As Represented By The Department Of Health And Human Services Autoantibody detection for cancer diagnostics
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
SE0402536D0 (sv) * 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
PT1889059E (pt) * 2005-05-27 2009-10-01 Oncimmune Ltd Métodos de imunoensaio melhorados
WO2006132587A1 (en) * 2005-06-10 2006-12-14 Forskarpatent I Syd Ab Tumour marker in brca2 associated breast cancer
WO2007079284A2 (en) * 2005-11-10 2007-07-12 University Of Kentucky Lung cancer diagnostic assay
US8329635B2 (en) 2006-06-20 2012-12-11 Bracco Imaging S.P.A. Method for the preparation of specific antibodies against saccharidic antigens
JP2010507069A (ja) * 2006-07-08 2010-03-04 ユニバーシティー オブ ケンタッキー リサーチ ファンデーション 肺癌診断アッセイ
CN101632020B (zh) * 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
PL2062053T3 (pl) * 2006-09-13 2013-05-31 Oncimmune Ltd Ulepszone sposoby testowania immunologicznego
GB2441824A (en) * 2006-09-13 2008-03-19 Oncimmune Ltd Immunoassay method
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
US8741581B2 (en) 2009-04-27 2014-06-03 Technion Research And Development Foundation Ltd. Markers for cancer detection
JP2012531581A (ja) * 2009-06-23 2012-12-10 イベントゥス、ダイアグノスティックス、イスラエル、リミテッド 癌の検出のための方法およびシステム
US20130189707A1 (en) * 2010-01-26 2013-07-25 Svetlana Alexandrovna Sergeeva Method of determination of autoantibody level by means of enzyme immunoassay
EP3450979A3 (en) 2010-03-17 2019-04-24 The Regents of The University of Michigan Using phage epitopes to profile the immune response
WO2011120015A2 (en) * 2010-03-26 2011-09-29 Armune Biosciences, Inc. Method and system of particle-coupled phage epitope
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
CA2806381C (en) 2010-08-13 2019-11-05 Joshua Labaer Biomarkers for the early detection of breast cancer
US20130040839A1 (en) * 2011-06-27 2013-02-14 Ambergen, Inc. Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery
WO2013023162A2 (en) * 2011-08-10 2013-02-14 Genus Oncology, Llc Anti-muc1 antibodies for cancer diagnostics
BR112017003310A2 (pt) 2014-08-18 2018-01-23 Basf Se polibutadienóis modificados por poliéster para produção de elastômeros de poliuretano e poliuretanos termoplásticos
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
US20210132061A1 (en) * 2017-04-14 2021-05-06 The Regents Of The University Of California Methods and Devices for Performing Auto-Antibody Assays
CN109448790B (zh) * 2018-11-19 2021-11-09 上海科技大学 一种确定肿瘤免疫治疗标志物的存储介质、设备及装置
CN116324412A (zh) 2020-07-14 2023-06-23 昂西免疫有限公司 抗原组合用于检测肺癌中的自身抗体的用途
GB2600701A (en) 2020-11-04 2022-05-11 Oncimmune Ltd Antibody assay
CN112345755B (zh) * 2020-09-23 2023-06-16 杭州凯保罗生物科技有限公司 乳腺癌的生物标志物及其应用
WO2023091714A1 (en) * 2021-11-18 2023-05-25 Greenwich Lifesciences, Inc. Methods for assessing an immune response and predicting cancer recurrence and assessment of current and prior cancer status
GB2622246A (en) 2022-09-08 2024-03-13 Oncimmune Germany Gmbh Antibody assay

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241044A (en) 1978-12-28 1980-12-23 Abbott Laboratories Method of diagnosing cancer by detecting elevated anti-T antibody activity
NZ211453A (en) * 1984-03-22 1989-01-06 Biotechnology Research Enterpr Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides
ATE77700T1 (de) 1986-03-10 1992-07-15 Imre Corp Immunkomplextestverfahren.
AU2253688A (en) 1987-07-24 1989-03-01 Xoma Corporation Methods for breast cancer detection
US4937185A (en) 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
US7282345B1 (en) 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5157020A (en) 1990-05-24 1992-10-20 Research Corporation Tech., Inc. Synthetic senescent cell antigen
DK9091D0 (da) 1991-01-18 1991-01-18 Novo Nordisk As Fremgangsmaade til fremstilling af antistoffer
DE4120412C1 (el) 1991-06-20 1993-01-07 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
US6280962B1 (en) 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
US6322989B1 (en) * 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993021529A1 (en) * 1992-04-14 1993-10-28 Duke University Method of detecting tumors containing complexes of p53 and hsp70
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5763164A (en) * 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
US5747268A (en) * 1993-04-22 1998-05-05 Dade International Inc. Tumor marker control
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5721105A (en) 1994-02-20 1998-02-24 B.R.A.H.M.S. Diagnostica Gmbh Method for the immunological determination of proteins and kit for carrying out the method
JPH07294530A (ja) 1994-04-20 1995-11-10 Nippon Igaku Rinshiyou Kensa Kenkyusho:Kk 病原体に対する体液中の抗体検出法
CA2148971A1 (en) 1994-05-26 1995-11-27 Izak Bahar Calibrator matrix
DE69518919T2 (de) 1994-06-24 2001-03-29 Vladimir P Torchilin Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US5561049A (en) 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5876728A (en) * 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
GB9521544D0 (en) * 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
JPH09189702A (ja) 1996-01-09 1997-07-22 Hitachi Chem Co Ltd 抗ムチン抗体の測定法、癌の測定法及び癌診断薬
JPH09229933A (ja) 1996-02-27 1997-09-05 Kokichi Sugano ｐ５３蛋白質に対する自己抗体検出法
WO1998006746A2 (en) * 1996-08-16 1998-02-19 The Johns Hopkins University School Of Medicine Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
EP1019727A1 (en) * 1997-06-03 2000-07-19 Amdl, Inc Immunoassay for the detection of cancer
DE19805815C1 (de) 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostikum zum Erkennen der autoimmunen Hepatitis
JP4083855B2 (ja) 1998-02-16 2008-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 肺癌予後検査方法
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
AUPP349098A0 (en) 1998-05-13 1998-06-04 South Eastern Sydney Area Health Service A method of monitoring pancreatic tissue viability
FR2780161B1 (fr) 1998-06-17 2000-09-29 Centre Nat Rech Scient Procede de diagnostic precoce du cancer base sur la recherche d'auto-anticorps diriges contre la proteine csk et trousse pour sa mise en oeuvre
IL142971A0 (en) 1998-11-05 2002-04-21 Univ Michigan S100 proteins and autoantibodies as serum markers for cancer
US6387639B1 (en) * 1998-11-10 2002-05-14 Sloan-Kettering Institute For Cancer Research Ma family polypeptides and anti-Ma antibodies
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US7807810B2 (en) 1999-04-08 2010-10-05 The Ohio State University Research Foundation Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20020064801A1 (en) 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20030138860A1 (en) 2000-06-14 2003-07-24 Robertson John Forsyth Russell Cancer detection methods and reagents
JP2005506515A (ja) 2000-12-13 2005-03-03 バイオ−ラッド ラボラトリーズ，インコーポレイティド 多種検定用の標準希釈液
WO2003073101A2 (en) 2001-06-21 2003-09-04 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
US20030049692A1 (en) 2002-09-16 2003-03-13 Norman Latov Detection of anti-glycolipid antibodies by latex agglutination assay
GB2424070B (en) 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
US7283245B2 (en) * 2004-01-20 2007-10-16 General Electric Company Handheld device with a disposable element for chemical analysis of multiple analytes
JP2005352771A (ja) * 2004-06-10 2005-12-22 Hitachi Software Eng Co Ltd 発現プロファイルによるパターン認識システム
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
EP1789435B1 (en) * 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
PL2062053T3 (pl) 2006-09-13 2013-05-31 Oncimmune Ltd Ulepszone sposoby testowania immunologicznego
WO2008103188A1 (en) * 2007-02-23 2008-08-28 Alfalight, Inc High efficiency partial distributed feedback (p-dfb) laser
GB0725239D0 (en) 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay

Also Published As

Publication number Publication date
EP1710253A2 (en) 2006-10-11
WO1999058978A3 (en) 2000-01-20
DE69929185T2 (de) 2006-08-31
US9696319B2 (en) 2017-07-04
EP1731619A3 (en) 2007-09-26
EP1731619A2 (en) 2006-12-13
ES2443096T3 (es) 2014-02-17
PT1731619E (pt) 2014-03-10
EP1710253A3 (en) 2007-10-31
WO1999058978A2 (en) 1999-11-18
US20120115749A1 (en) 2012-05-10
US8114604B2 (en) 2012-02-14
EP1078264A2 (en) 2001-02-28
ES2257048T3 (es) 2006-07-16
EP1731619B1 (en) 2013-12-18
DK1731619T3 (en) 2014-03-24
US20080153113A1 (en) 2008-06-26
US20130090251A1 (en) 2013-04-11
AU3838899A (en) 1999-11-29
DE69929185D1 (de) 2006-02-02
DK1078264T3 (da) 2006-05-15
SI1078264T1 (sl) 2006-06-30
GB9810040D0 (en) 1998-07-08
US7402403B1 (en) 2008-07-22
EP1078264B1 (en) 2005-12-28
ATE314651T1 (de) 2006-01-15
PT1078264E (pt) 2006-05-31

Similar Documents

Publication Publication Date Title
CY1115366T1 (el) Δεικτες ογκου
CA2384579A1 (en) Early cancer tumor marker
Edwards et al. Proteins of human urine. II. Identification by two-dimensional electrophoresis of a new candidate marker for prostatic cancer.
WO2002057787A3 (en) Detection of survivin in the biological fluids of cancer patients
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
PT838680E (pt) Determinacao de antigenios complexados especificos da prostata
MY133942A (en) Reagent test strip for analyte determination having hemolyzing agent
Shimizu et al. Establishment of assay kits for the determination of microheterogeneities of alpha-fetoprotein using lectin-affinity electrophoresis
WO2004112570A3 (en) Detection of survivin in the biological fluids of cancer patients
IL142971A0 (en) S100 proteins and autoantibodies as serum markers for cancer
KR890015714A (ko) 폐암의 조기 검출 방법
DK155967C (da) Fremgangsmaade samt kit til bestemmelse af antistoffer mod oploeselige antigener
DE3850249D1 (de) Nachweis von analyt in partikel enthaltenden proben.
IT8921788A0 (it) Reattivo utile per la rilevazione e la determinazione quantitativa dei leucociti in fluidi biologici.
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
DK0958500T3 (da) Immunohistokemisk påvisningsassay for carcinomproliferationsstatus
DE69209063D1 (de) Vorprüfung von prostatakrebs durch serum prostatischen spezifischen antigen
WO1998046993A3 (en) Method for diagnosing cancer by measuring the presence of creatine kinase inhibitor
DE69811157T2 (de) Immunoassay zur Bestimmung von PSA-ACT
WO2001086292A3 (en) Ipg assay
FI104219B1 (fi) Diagnostinen menetelmä ja testaustarvikesarja multippeliskleroosin määrittämiseksi